Zenotech Laboratories Ltd banner
Z

Zenotech Laboratories Ltd
BSE:532039

Watchlist Manager
Zenotech Laboratories Ltd
BSE:532039
Watchlist
Price: 47 INR 0.99%
Market Cap: ₹2.9B

Zenotech Laboratories Ltd
Other Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Zenotech Laboratories Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zenotech Laboratories Ltd
BSE:532039
Other Receivables
₹0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Other Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hester Biosciences Ltd
NSE:HESTERBIO
Other Receivables
₹4.9m
CAGR 3-Years
-57%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Other Receivables
₹0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Other Receivables
₹29.7m
CAGR 3-Years
11%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Zenotech Laboratories Ltd
Glance View

Market Cap
2.9B INR
Industry
Biotechnology

Zenotech Laboratories Ltd. engages in the manufacture and marketing of pharmaceuticals products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing and marketing biotechnology and pharmaceuticals products. The Company’s injectables product portfolio primarily serves niche therapy areas, such as oncology and anesthesiology. The firm has a manufacturing facility at Turkapally village, Shamirpet Mandal, Telangana.

ZENOTECH Intrinsic Value
38.52 INR
Overvaluation 18%
Intrinsic Value
Price ₹47
Z

See Also

What is Zenotech Laboratories Ltd's Other Receivables?
Other Receivables
0 INR

Based on the financial report for Dec 31, 2025, Zenotech Laboratories Ltd's Other Receivables amounts to 0 INR.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett